Number of shares present or represented at the meeting (including abstentions): | 40,422,608 |
Number of issued shares: | 151,626,107 |
Percentage of issued shares present or represented at the meeting: | 26.66% |
Number of voting securities present or represented at the meeting (including abstentions) | 332,857,067 |
Number of issued voting securities | 454,878,321 |
Percentage of voting securities present or represented at the meeting | 73.17% |
Total number of shares and voting securities present or represented at the meeting (including abstentions): | 373,279,675 |
Item | Subject Matter | Number of votes cast FOR | % of votes cast FOR | Number of votes cast AGAINST | % of votes cast AGAINST | Abstentions | Total number of shares and voting securities present or represented |
First Item | Presentation of the special report of the board of directors of the Company (as required pursuant to Article 441-7 of the Luxembourg law of 10 August 1915 on commercial companies, | n/a | n/a | n/a | n/a | n/a | 373,279,675 |
as amended) on any transaction, since the last general meeting of the Company, in respect of which any of the directors declared to have an interest conflicting with that of the Company. | |||||||
Second Item | Presentation of (i) the combined management report of the board of directors of the Company in respect of the stand-alone annual financial statements of the Company and the consolidated financial statements of the Company and its group for the financial year ending 31 December 2022, (ii) the report of the independent auditor of the Company in respect of the stand-alone annual financial statements of the Company and its group for the financial year ending 31 December 2022 and (iii) the report of the independent auditor of the Company in respect of the consolidated financial statements of the Company and its group for the financial year ending 31 December 2022. | n/a | n/a | n/a | n/a | n/a | 373,279,675 |
Third Item | Approval of the audited standalone annual accounts of the Company for the financial year ending 31 December 2024 | 350,212,068 | 96,08% | 14,300,000 | 3,92% | 8,767,607 | 373,279,675 |
Fourth Item | Approval of the audited consolidated financial statements of the Company and its group for the financial year ending 31 December 2024 | 350,212,068 | 96,08% | 14,300,000 | 3,92% | 8,767,607 | 373,279,675 |
Fifth Item | Approval of the allocation of the statutory financial results for the financial year ending 31 December 2024 | 350,212,068 | 96,08% | 14,300,000 | 3,92% | 8,767,607 | 373,279,675 |
Sixth item | Approval of the granting of discharge (quitus) to all directors who held office during the financial year ending 31 December 2024 in respect of the performance of their duties during that financial year.. | 350,212,068 | 96,08% | 14,300,000 | 3,92% | 8,767,607 | 373,279,675 |
Seventh Item | Approval of the appointment, as recommended by the board of directors, of AVEGA Revision S.à r.l. as the approved statutory auditor/approved audit firm to perform the statutory audit of the standalone annual accounts and consolidated financial | 350,212,067 | 96,08% | 14,300,001 | 3,92% | 8,767,607 | 373,279,675 |
statements of the Company for the financial year ended 31 December 2025 with such engagement to last until the annual general meeting of the Company to take place in 2026. | |||||||
Eight Item | Re-appointment of Mr. Thilo Schmid as director of the Company for a period running from the date of this AGM until the annual general meeting to take place in the year 2027.. | 340,224,802 | 93,34% | 24,287,266 | 6,66% | 8,767,607 | 373,279,675 |
Ninth Item | Confirmation of the appointment of Dr. Karl Reinitzhuber as a director of the Company who was appointed by co-optation since the last general meeting of shareholders of the Company (for declaratory purposes only), and the appointment of Dr. Karl Reinitzhuber as director of the Company for a period running from the date of this AGM until the annual general meeting to take place in the year 2027.. | 350,212,068 | 96,08% | 14,300,000 | 3,92% | 8,767,607 | 373,279,675 |
Tenth Item | Approval of additional directors' remuneration, applicable for the financial | 339,644,810 | 93,18% | 24,867,258 | 6,82% | 8,767,607 | 373,279,675 |
year 2025, in an aggregate gross amount of EUR 6,000,000.00, and authorisation to the board of directors of the Company to allocate this aggregate amount among the members of the board of directors and to determine the further implementation modalities and payment conditions. | |||||||
Eleventh Item | Approval (on an advisory and non-binding basis) of on adapted version of the remuneration policy of the Company | 339,522,226 | 93,14% | 24,989,842 | 6,86% | 8,767,607 | 373,279,675 |
Twelfth Item | Approval (on an advisory and non-binding basis) of the remuneration report of the Company for the financial year ending 31 December 2024.. | 339,644,810 | 93,18% | 24,867,258 | 6,82% | 8,767,607 | 373,279,675 |